Sanofi, Regeneron broaden alliance to find their next Dupixent

Summary

Sanofi and Regeneron have broadened their alliance with a $1 billion upfront payment to develop long-acting antibody drugs targeting the same mechanisms as their blockbuster Dupixent. The collaboration aims to discover the companies' next major anti-inflammatory asset.